# Diabetes Research Hub — Monitor Review Report

**Run date:** 2026-06-13 (automated, unattended)
**Reviewer:** Hub Monitor scheduled task
**Scope:** Review of latest script outputs, snapshot diffs, gap analysis, and a 7-day breaking-news web check. This is a **read-only review** — no hub files were modified.

---

## TL;DR — What's Actionable

1. **Retatrutide Phase 3 (TRIUMPH program) read out at ADA Scientific Sessions, June 5–8, 2026** — first triple-hormone (GIP/GLP-1/glucagon) therapy for T2D + obesity, with complication benefits (OSA, knee OA pain). This is the most significant external item this week and is corroborated by a new cross-domain PubMed hit. *Worth a tracker entry + evidence review.*
2. **PubMed/gap data is one day stale** relative to trials. `pubmed_recent_latest.json` and `literature_gap_report.md` are dated **2026-06-12**; clinical-trials data refreshed cleanly to **2026-06-13**. Re-run the PubMed alert script to resync if a same-day view is needed.
3. **Hub-wide staleness flag:** `hub_monitor.py` reports **709 result files older than 14 days**. Most are dated daily snapshots (expected), but worth confirming no live analysis output is silently stale.
4. **Trial activity is quiet:** only 4 new / 2 removed trials vs. yesterday, **0 status changes, 0 newly posted results.** Nothing urgent in the trial feed.

---

## File System Status

| File | Last modified | Status |
|------|--------------|--------|
| `clinical_trials_latest.json` | 2026-06-13 07:04 | ✅ Current |
| `clinical_trials_summary.md` | 2026-06-13 07:04 | ✅ Current |
| `hub_monitor_report.md` | 2026-06-13 07:05 | ✅ Current |
| `pubmed_recent_latest.json` | 2026-06-12 07:05 | ⚠️ 1 day old |
| `literature_gap_report.md` | 2026-06-12 08:08 | ⚠️ 1 day old |
| `literature_gap_data.json` | 2026-04-20 15:35 | ⚠️ ~54 days old (raw gap dataset) |

**Notes:**
- All four expected core outputs exist; none missing.
- The human-readable gap *report* (`literature_gap_report.md`) was regenerated 06-12, but the underlying gap *dataset* (`literature_gap_data.json`) dates to 2026-04-20. The report appears to be driven by a newer evidence pipeline (`gap_evidence.json`, 06-12) rather than the April raw file.
- `hub_monitor.py` review flag: **709 result files older than 14 days.** Expected for archived daily snapshots; flagged here only for awareness.
- A stale Excel lock file (`.~lock.Diabetes_Research_Tracker.xlsx#`) is present in the hub root — the tracker may be open/locked on the user's machine.

---

## Clinical Trial Changes (vs. 2026-06-12 snapshot)

**Diff summary:** 4 new · 2 removed · 0 status changes · 0 newly posted results.
**Corpus totals:** 809 unique trials — 262 RECRUITING, 141 NOT_YET_RECRUITING, 292 COMPLETED. 124 are PHASE3; **46 are Phase 3 + RECRUITING.**

### New trials
- **NCT07645079** — Steno Diabetes Center Copenhagen — *Automated Insulin Delivery vs. Daily Injections for Hospital Diabetes* (NOT_YET_RECRUITING)
- **NCT07646067** — Ideal Medical Technologies — *Closed-Loop Glucose Control in a Simulated ICU Setting* (NOT_YET_RECRUITING)
- **NCT07645313** — Yuwell Group — *Accuracy/Safety of Anytime 5Pro & 4Pro CGM Systems* (NOT_YET_RECRUITING)
- **NCT07645482** — Beni-Suef University — *Rhythmic Electrical Modulated Stimulation in Peripheral [Neuropathy]* (NOT_YET_RECRUITING)

All four are device/closed-loop/neuro-stimulation studies — none are pharma cell-therapy or immunotherapy of high strategic interest.

### Removed trials
- **NCT07097415** — CGM in operative setting (was RECRUITING)
- **NCT06582719** — GPT-based nutrition/diabetes coaching (was RECRUITING)

### Key Phase 3 programs being tracked (status this run)
| Therapy / Program | Sponsor | Notable Phase 3 trials | Status |
|---|---|---|---|
| **VX-880 (zimislecel)** islet cell therapy | Vertex | NCT04786262, NCT06832410 | RECRUITING |
| **Baricitinib** (beta-cell preservation) | Eli Lilly | NCT07222332, NCT07222137 | RECRUITING |
| **Orforglipron** (oral GLP-1) | Eli Lilly | NCT07613307 (T2D) | NOT_YET_RECRUITING; others ACTIVE/COMPLETED |
| **Retatrutide** (triple agonist) | Eli Lilly | NCT06297603, NCT06260722, NCT05929079 | ACTIVE_NOT_RECRUITING |
| **CagriSema** | Novo Nordisk | NCT07282613, NCT06534411, NCT07564414 | RECRUITING / NOT_YET / ACTIVE |
| **Insulin icodec (weekly)** | Novo Nordisk | NCT07076199, NCT07400107 | RECRUITING / NOT_YET |
| **Teplizumab** | various | NCT06791291 (Japan, P2), NCT05757713 (peds, P4) | RECRUITING / ACTIVE |

No **Sana Biotechnology** trials currently appear in the diabetes corpus. Vertex's hypoimmune **VX-264** (NCT05791201) remains ACTIVE_NOT_RECRUITING (P1/2).

> ⚠️ Data note: the `has_results` field is `false` for all 809 trials in the latest export even though 292 fall in the "Recently Completed with Results" category. The `has_results`/`results_posted` flags appear not to be populated by the current export — "newly posted results" detection may be unreliable until that field is fixed in `baseline_clinical_trials.py`.

---

## PubMed Highlights (data as of 2026-06-12, 30-day lookback, 165 unique papers)

### Cross-domain papers (highest priority — 13 this snapshot)
The strongest cluster is **T1D immunotherapy ↔ teplizumab** (4 papers), reflecting continued teplizumab momentum:
- **[42163482]** Extracellular-vesicle proteins as predictive biomarkers — *T1D Stem Cell Cure + Immunotherapy + teplizumab* (triple-domain)
- **[42267680]** Early teplizumab treatment response via continuous glucose monitoring — *Immunotherapy + teplizumab*
- **[42269843]** Shared immune pathways in MS and T1D — *Immunotherapy + teplizumab*
- **[42221148]** Efficacy/safety of teplizumab in Stage 3 T1D — *Immunotherapy + teplizumab*

Other notable cross-domain hits:
- **[42277427]** Lentiviral GLP-1 gene therapy → stage-dependent β-cell regeneration — *GLP-1 + Gene Therapy* (novel mechanism)
- **[42259339]** Orforglipron vs. dapagliflozin head-to-head in T2D — *two key therapies*
- **[42198313]** / **[42264536]** Retatrutide papers — *retatrutide + CagriSema / GLP-1* (aligns with ADA readout below)
- **[42276507]** / **[42262824]** Biomarker ↔ complications crossovers (oxidative stress + retinal imaging; urine aquaporin-5 in DKD)

### Key-therapy mentions (paper counts)
dapagliflozin 51 · retatrutide 10 · orforglipron 8 · CagriSema 8 · teplizumab 8 · icodec 7 · baricitinib 5 · **zimislecel 0**.

### Volume trends
13 of 16 alert domains are saturated at the 10-paper cap; under-active domains are **Drug Repurposing (4)** and **GLP-1 Pharmacogenomics (3)** — consistent with their status as small, specialized fields and with the gap analysis below.

---

## Gap Analysis Summary (BRONZE confidence — single analytical source)

Top under-researched intersections (Gap Score 100 = essentially no co-publication):

| Rank | Intersection | Joint Pubs | Why it may matter |
|---|---|---|---|
| 1 | **Beta Cell Regen × Health Equity** | 0 | No equity analysis of who can access emerging regenerative/cell therapies |
| 2 | **Insulin Resistance × Islet Transplant** | 1 | IR in graft recipients affects survival; barely studied |
| 3 | **Islet Transplant × Drug Repurposing** | 0 | Existing immunosuppressants could be screened for islet protection |
| 4 | **Islet Transplant × Health Equity** | 0 | Islet transplant access limited to select centers; no equity work |
| 5 | **Gene Therapy × LADA** | 0 | LADA's autoimmune mechanism makes it a gene-therapy candidate; no crossover |

### Alignment with Tier-1 Doctrine contribution areas
Several top gaps sit squarely in our **Tier-1** mandate and are strong candidate projects:
- **Drug Repurposing** (Tier-1 #4) appears in gaps #3 + others → directly supports the islet-immunosuppressant repurposing work already underway in the hub.
- **Health Equity / Epidemiology** (Tier-1 #6) recurs across gaps #1, #4, and many unclassified pairs → equity overlays on cell/immunotherapies are a defensible, data-available contribution.
- **Literature Synthesis & Gap Analysis** (Tier-1 #2) is the engine producing this list.

All gap classifications remain **BRONZE / preliminary** per the Research Doctrine and require expert confirmation + cross-check against Cochrane/PROSPERO before any claim is published.

---

## Breaking News (7-day web check)

**🔬 Significant — Retatrutide Phase 3 (TRIUMPH) read out at ADA Scientific Sessions, New Orleans, June 5–8, 2026.**
Described as the first triple-hormone (GIP + GLP-1 + glucagon) agonist for T2D + obesity to report Phase 3 data, with positive A1C/weight outcomes **plus** benefits on obstructive sleep apnea and knee-osteoarthritis pain (once-weekly injection). This corroborates the new retatrutide PubMed hits ([42264536], [42198313]) and is the week's headline external development.
*Evidence level: press/conference-presentation tier — GOLD requires the peer-reviewed primary publications once posted.*

**Regulatory context (slightly older than 7 days, for completeness):**
- **Awiqli (insulin icodec)** — approved 2026-03-26 as first once-weekly basal insulin (T2D).
- **Generic dapagliflozin (Farxiga)** — first generics approved 2026-04-07 (HF-hospitalization-risk indication).
- **Langlara (insulin glargine-aldy)** — interchangeable Lantus biosimilar, approved 2026-04-29.

No *new* FDA diabetes approval was identified within the last 7 days.

---

## Recommended Actions

1. **Add a tracker entry for the retatrutide TRIUMPH Phase 3 readout** (ADA 2026-06-05/08). Tag evidence level as conference/press until peer-reviewed publications appear; queue PMIDs [42264536] and [42198313] for the evidence pipeline.
2. **Re-sync PubMed + gap data** so it matches the 06-13 trial snapshot:
   `python baseline_pubmed_alerts.py` and, if desired, `python project1_literature_gap_analysis.py` (raw `literature_gap_data.json` dates to 2026-04-20).
3. **Fix `has_results` / `results_posted` population in `baseline_clinical_trials.py`** — currently `false` for all 809 trials, which blinds the "newly posted results" detector.
4. **Confirm the 709 stale-file flag is benign** (expected for archived daily snapshots) and consider archiving older `clinical_trials_snapshot_*` / `pubmed_recent_snapshot_*` files out of `Analysis/Results/` to reduce monitor noise.
5. **Release the Excel lock** — `.~lock.Diabetes_Research_Tracker.xlsx#` suggests the tracker is open on the user's machine; close it before the next automated tracker write.
6. **Prioritize the Tier-1-aligned gaps for synthesis:** Islet Transplant × Drug Repurposing and Beta Cell Regen × Health Equity are the most defensible next literature-synthesis targets given existing hub assets. Validate each against Cochrane/PROSPERO first (Doctrine requirement).

---

*Generated by the Diabetes Hub Monitor scheduled task — read-only review run, 2026-06-13. No source files were modified. New external claims carry the evidence level noted inline, per RESEARCH_DOCTRINE.md.*
